Limited Sustained Remission After Nucleos(t)ide Analog Withdrawal: Results From a Large, Global, Multiethnic Cohort of Patients With Chronic Hepatitis B (RETRACT-B Study).
Grishma HirodeBettina E HansenChien-Hung ChenTung-Hung SuGrace Lai-Hung WongWai Kay SetoArno Furquim d'AlmeidaMargarita PapatheodoridiSylvia M BrakenhoffSabela LensHannah S J ChoiRong-Nan ChienJordan J FeldXavier FornsMilan J SonneveldGeorgios PapatheodoridisThomas VanwolleghemMan Fung YuenHenry Lik Yuen ChanJia-Horng KaoYao-Chun HsuMarkus CornbergWen-Juei JengHarry L A Janssennull nullPublished in: The American journal of gastroenterology (2024)
Despite allowing for HBV DNA and ALT fluctuations within the first 12 months off-treatment, most patients without HBsAg loss did not maintain a sustained response thereafter. The best candidates for NA withdrawal are patients with low HBsAg levels at NA cessation, and those without profound or recurrent virological and biochemical relapses in the first off-treatment year.